226 related articles for article (PubMed ID: 35003069)
1. Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.
Mao R; Yang F; Zhang T; Li J
Front Immunol; 2021; 12():756282. PubMed ID: 35003069
[TBL] [Abstract][Full Text] [Related]
2. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
3. Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy.
Wu X; Wang X; Zhao Y; Li K; Yu B; Zhang J
Int J Med Sci; 2021; 18(7):1657-1669. PubMed ID: 33746582
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
5. Prediction of clinical prognosis in cutaneous melanoma using an immune-related gene pair signature.
Yang Y; Long X; Li G; Yu X; Liu Y; Li K; Tian X
Bioengineered; 2021 Dec; 12(1):1803-1812. PubMed ID: 34047683
[TBL] [Abstract][Full Text] [Related]
6. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma.
Hu B; Wei Q; Zhou C; Ju M; Wang L; Chen L; Li Z; Wei M; He M; Zhao L
Int Immunopharmacol; 2020 Dec; 89(Pt A):107162. PubMed ID: 33168410
[TBL] [Abstract][Full Text] [Related]
7. Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma.
Qu Y; Zhang S; Zhang Y; Feng X; Wang F
Virchows Arch; 2021 May; 478(5):943-959. PubMed ID: 33179141
[TBL] [Abstract][Full Text] [Related]
8. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
9. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
10. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
Sheng Y; Tong L; Geyu L
Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of Tumor Immunogenicity Based Gene Signature for Skin Cancer Risk Stratification.
Yavartanoo M; Yi GS
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769455
[TBL] [Abstract][Full Text] [Related]
12. Construction of an immune-related gene signature for prediction of prognosis in patients with cervical cancer.
Mei J; Xing Y; Lv J; Gu D; Pan J; Zhang Y; Liu J
Int Immunopharmacol; 2020 Nov; 88():106882. PubMed ID: 32799114
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma.
Liu Y; Chen Y; Hu X; Meng J; Li X
Biomed Res Int; 2020; 2020():8509805. PubMed ID: 32908921
[TBL] [Abstract][Full Text] [Related]
14. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
15. Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors.
Bubie A; Gonzalez-Kozlova E; Akers N; Villanueva A; Losic B
Sci Rep; 2020 Mar; 10(1):5062. PubMed ID: 32193450
[TBL] [Abstract][Full Text] [Related]
16. A Novel Signature of 23 Immunity-Related Gene Pairs Is Prognostic of Cutaneous Melanoma.
Xue YN; Xue YN; Wang ZC; Mo YZ; Wang PY; Tan WQ
Front Immunol; 2020; 11():576914. PubMed ID: 33193373
[TBL] [Abstract][Full Text] [Related]
17. A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8
Wang Z; Peng M
Sci Rep; 2021 Apr; 11(1):9164. PubMed ID: 33911146
[TBL] [Abstract][Full Text] [Related]
18. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
[TBL] [Abstract][Full Text] [Related]
19. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.
Li LQ; Zhang LH; Zhang Y; Lu XC; Zhang Y; Liu YK; Khader MA; Jia-Wen ; Tao-Liu ; Li JZ
Aging (Albany NY); 2020 Nov; 12(22):22906-22926. PubMed ID: 33203792
[TBL] [Abstract][Full Text] [Related]
20. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]